drugset
drugset / Trial / NCT01711034

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

NCT01711034 ↗

Phase 1 Completed 145 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.

Timeline

Start
2012-06
Primary completion
2015-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject OPB-111077 Small molecule 100 mg Oral
Subject OPB-111077 Small molecule 250 mg Oral
Subject OPB-111077 Small molecule 300 mg Oral
Subject OPB-111077 Small molecule 400 mg Oral

Indications

cancer